NEW YORK (GenomeWeb) – OpGen announced today that it has signed a supply agreement with Thermo Fisher Scientific to combine its Acuitas Rapid Test for Pathogen ID with Thermo Fisher's real-time PCR solutions.

The deal is intended to help support the commercialization of OpGen's rapid molecular products and informatics system to help combat multidrug-resistant infections, the company said. Combining genomic analysis with bioinformatics can help healthcare providers efficiently and accurately identify bacterial antibiotic susceptibility, it added.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.